PHILADELPHIA — (May, 1, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of molecular systems biolo…
PHILADELPHIA — (April 29, 2020) — The Wistar Institute and Batavia Biosciences announce the launch of a strategic collaboration aimed to streamline the clinical grade manufacture and global distrib…
PHILADELPHIA — (March 11, 2020) — Scientists at The Wistar Institute reported a sophisticated technology to simplify production of nanovaccines, a novel approach to vaccination that can robustly st…
PHILADELPHIA — (Feb. 19, 2020) — Scientists at The Wistar Institute discovered a novel pathway that enables detection of DNA in the cytoplasm and triggers inflammation and cellular senescence. This…
PHILADELPHIA — (Jan. 30, 2020) — Combining EZH2 inhibition and PARP1 inhibition may provide a new therapeutic strategy for ovarian cancers that have functional DNA damage repair and thus would not …
PHILADELPHIA — (Jan. 24, 2020) — In a study by The Wistar Institute and collaborators, a rare, African-specific variant of the TP53 gene called P47S causes iron accumulation in macrophages and othe…
PHILADELPHIA — (Jan. 23, 2020) — The Wistar Institute announces today that they are part of a team to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has infec…
PHILADELPHIA — (Jan. 11, 2020) — Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, …
PHILADELPHIA — (Dec. 19, 2019) — In the past six months, scientists at The Wistar Institute received funding from private foundations totaling $2,418,000 that will fuel new discoveries in cancer, i…
PHILADELPHIA — (Dec. 19, 2019) — A study from The Wistar Institute demonstrated that NAMPT, an enzyme critical for NAD+ biosynthesis, mediates selection of stem-like chemoresistant cells following …
